Cell therapy for limiting overzealous inflammatory reactions in tissue healing
US9220813B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2011 |
| Grant date | Dec 29, 2015 |
| Priority date | — |
| Expiry date | Sep 1, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.